SEARCH BY

Issuer directory Issuer directory
KEYWORDS
COMPANIES / ISIN
TYPE OF INFORMATION
INDUSTRY

Start search  ADVANCED SEARCH

COMPARTMENTS / INDICES

France
America
Asia
Oceania
Africa
Europe

CAC 40 NEWS

FEEDS

My RSS My Google Microsoft Live My Yahoo

COMPANY SEARCH RESULT

Sanofi-Aventis: Click to view the issuer\'s details

Last update : 29/03/2019  >View issuer details

2021.05.06 | 07:00 | Permanent Information Releases / General Company News

English version HTML (w) Mail

puce Sanofi establishes three-year collaboration with Stanford Medicine to accelerate immunology research - HTML (w)

2021.05.06 | 07:00 | Permanent Information Releases / General Company News

French version HTML (w) Mail

puce Sanofi noue une collaboration de trois ans avec Stanford Medicine pour intensifier sa recherche en immunologie  - HTML (w)

2021.05.03 | 18:00 | Share History / Voting Rights and Number of Shares

English version HTML (w) Mail

puce Sanofi: Information concerning the total number of voting rights and shares - March 2021 - HTML (w)

2021.05.03 | 18:00 | Share History / Voting Rights and Number of Shares

French version HTML (w) Mail

puce Sanofi: Informations relatives au nombre total de droits de vote et d’actions - Mars 2021 - HTML (w)

2021.04.30 | 17:56 | Permanent Information Releases / General Company News

English version HTML (w) Mail

puce Annual General Meeting of April 30, 2021 - HTML (w)

2021.04.30 | 17:56 | Permanent Information Releases / General Company News

French version HTML (w) Mail

puce Assemblée Générale Annuelle du 30 avril 2021 - HTML (w)

2021.04.28 | 07:30 | Periodic information / 1st Quarter Information

English version HTML (w) Mail

puce Sanofi continued its growth trajectory. Strong increase in Q1 2021 business EPS(1) at CER - HTML (w)

2021.04.28 | 07:30 | Periodic information / 1st Quarter Information

French version HTML (w) Mail

puce Sanofi poursuit sa trajectoire de croissance. Forte hausse du BNPA des activités(1) au T1 2021 à TCC - HTML (w)

2021.04.26 | 08:00 | Permanent Information Releases / General Company News

English version HTML (w) Mail

puce Nirsevimab demonstrated protection against respiratory syncytial virus disease in healthy infants in Phase 3 trial - HTML (w)

Pages : 1 - 2 - 3 - 4 - 5 - 6 - 7 - 8 - 9 - 10 / Doc nb : 3076